A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Clinical trial NCT06500702 · RECRUITING
Trial details
- NCT number
- NCT06500702
- Sponsor
- Sanofi
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-19
- Primary completion
- 2026-12-23
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.